(IDYA) Ideaya Biosciences - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US45166A1025

Kinase Inhibitor, Mat2a Inhibitor, Dll3 Adc, Werner Helicase, Parp Glycohydrolase

Biotechnology
Market Cap in USD: 3,194m
IPO / Inception: 2019-05-23
12m vs SPY: 35.7%

EPS (Earnings per Share)

EPS (Earnings per Share) of IDYA over the last years for every Quarter: "2020-12": -0.18, "2021-03": -0.28, "2021-06": -0.33, "2021-09": -0.31, "2021-12": -0.47, "2022-03": -0.36, "2022-06": -0.57, "2022-09": 0.04, "2022-12": -0.5, "2023-03": -0.49, "2023-06": -0.5, "2023-09": -0.46, "2023-12": -0.52, "2024-03": -0.53, "2024-06": -0.68, "2024-09": -0.6, "2024-12": -1.49, "2025-03": -0.82, "2025-06": -0.88, "2025-09": 1.33, "2025-12": 0,
EPS CAGR: 7.34%
EPS Trend: 12.8%
Last SUE: 1.19
Qual. Beats: 2

Revenue

Revenue of IDYA over the last years for every Quarter: 2020-12: 10.571, 2021-03: 7.247, 2021-06: 8.756, 2021-09: 8.976, 2021-12: 2.963, 2022-03: 11.359, 2022-06: 5.851, 2022-09: 29.699, 2022-12: 4.022, 2023-03: 7.88, 2023-06: 3.544, 2023-09: 8.038, 2023-12: 3.923, 2024-03: 0, 2024-06: 0, 2024-09: 0, 2024-12: 7, 2025-03: 0, 2025-06: 0, 2025-09: 207.834, 2025-12: null,
Rev. CAGR: 210.64%
Rev. Trend: -21.5%
Last SUE: 4.00
Qual. Beats: 1

Dividends

Currently no dividends paid
Risk via 5d forecast
Volatility 51.4%
Value at Risk 5%th 82.7%
Relative Tail Risk -2.18%
Reward TTM
Sharpe Ratio 1.12
Alpha 41.24
CAGR/Max DD 0.40
Character TTM
Hurst Exponent 0.355
Beta 0.990
Beta Downside 0.663
Drawdowns 3y
Max DD 69.23%
Mean DD 25.40%
Median DD 20.69%

Description: IDYA Ideaya Biosciences January 13, 2026

Ideaya Biosciences (NASDAQ: IDYA) is a U.S.-based precision-medicine oncology company that builds its pipeline around molecular-diagnostic-selected patient cohorts. Its lead assets include IDE196 (PKC inhibitor for GNAQ/GNA11-mutant cancers) in a combined Phase 2/3 study, IDE397 (MAT2A inhibitor for MTAP-deleted solid tumors) in Phase 2, and several early-stage programs such as IDE849 (DLL3-ADC for SCLC) and IDE275 (WRN helicase inhibitor for MSI-high tumors). The firm also runs preclinical discovery platforms (DECIPHER CRISPR library, INQUIRE AI engine) and maintains research alliances with GSK, Pfizer, Gilead, Merck, and leading academic institutions.

As of the latest 10-Q (Q3 2024), Ideaya reported cash and cash equivalents of roughly $120 million, giving it an estimated 12-month runway at current burn rates (~$10-12 million per quarter). The companys market capitalization hovers around $550 million, reflecting a typical biotech discount for early-stage pipelines lacking FDA-approved products. Sector-wide, oncology biotech R&D spend grew ~8 % YoY in 2023, driven by increasing investor appetite for biomarker-driven therapies, while the average time from Phase 1 to market in oncology remains >7 years, underscoring the long-term risk profile of Ideaya’s candidates.

If you want a data-rich, quantitative view of how Ideaya’s risk-adjusted valuation stacks up against peers, consider checking ValueRay’s analyst platform for deeper insights.

Piotroski VR‑10 (Strict, 0-10) 1.0

Net Income (-160.7m TTM) > 0 and > 6% of Revenue (6% = 12.9m TTM)
FCFTA -0.09 (>2.0%) and ΔFCFTA 3.47pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 343.6% (prev 22.7k%; Δ -22.4kpp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA -0.09 (>3.0%) and CFO -102.3m > Net Income -160.7m (YES >=105%, WARN >=100%)
NO Net Debt/EBITDA fails (EBITDA <= 0)
Current Ratio 12.44 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (89.7m) change vs 12m ago 4.06% (target <= -2.0% for YES)
Gross Margin 98.12% (prev -7.44%; Δ 105.6pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 17.72% (prev 0.32%; Δ 17.40pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
error: Interest Coverage Ratio cannot be calculated (needs EBITDA TTM and Interest Expense TTM)

Altman Z'' -5.95

(A) 0.62 = (Total Current Assets 802.7m - Total Current Liabilities 64.5m) / Total Assets 1.19b
(B) -0.55 = Retained Earnings (Balance) -653.3m / Total Assets 1.19b
(C) -0.13 = EBIT TTM -160.7m / Avg Total Assets 1.21b
(D) -6.99 = Book Value of Equity -651.2m / Total Liabilities 93.1m
Total Rating: -5.95 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 23.38

1. Piotroski 1.0pt
2. FCF Yield -4.33%
3. FCF Margin -49.06%
4. Debt/Equity 0.02
5. Debt/Ebitda 1.73
6. ROIC - WACC (= -21.76)%
7. RoE -15.55%
8. Rev. Trend -21.54%
9. EPS Trend 12.78%

What is the price of IDYA shares?

As of January 15, 2026, the stock is trading at USD 37.03 with a total of 1,546,592 shares traded.
Over the past week, the price has changed by -2.19%, over one month by +10.97%, over three months by +36.79% and over the past year by +62.84%.

Is IDYA a buy, sell or hold?

Ideaya Biosciences has received a consensus analysts rating of 4.69. Therefore, it is recommended to buy IDYA.
  • Strong Buy: 10
  • Buy: 2
  • Hold: 1
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the IDYA price?

Issuer Target Up/Down from current
Wallstreet Target Price 49.7 34.2%
Analysts Target Price 49.7 34.2%
ValueRay Target Price 45 21.5%

IDYA Fundamental Data Overview January 10, 2026

P/E Forward = 4.649
P/S = 14.8658
P/B = 2.9245
Revenue TTM = 214.8m USD
EBIT TTM = -160.7m USD
EBITDA TTM = -156.7m USD
Long Term Debt = 27.2m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 328.0k USD (from shortTermDebt, last quarter)
Debt = 27.2m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -271.7m USD (from netDebt column, last quarter)
Enterprise Value = 2.43b USD (3.19b + Debt 27.2m - CCE 786.9m)
Interest Coverage Ratio = unknown (Ebit TTM -160.7m / Interest Expense TTM 0.0)
EV/FCF = -23.09x (Enterprise Value 2.43b / FCF TTM -105.4m)
FCF Yield = -4.33% (FCF TTM -105.4m / Enterprise Value 2.43b)
FCF Margin = -49.06% (FCF TTM -105.4m / Revenue TTM 214.8m)
Net Margin = -74.82% (Net Income TTM -160.7m / Revenue TTM 214.8m)
Gross Margin = 98.12% ((Revenue TTM 214.8m - Cost of Revenue TTM 4.04m) / Revenue TTM)
Gross Margin QoQ = 99.50% (prev none%)
Tobins Q-Ratio = 2.05 (Enterprise Value 2.43b / Total Assets 1.19b)
Interest Expense / Debt = 92.01% (Interest Expense 25.1m / Debt 27.2m)
Taxrate = 21.0% (US default 21%)
NOPAT = -127.0m (EBIT -160.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 12.44 (Total Current Assets 802.7m / Total Current Liabilities 64.5m)
Debt / Equity = 0.02 (Debt 27.2m / totalStockholderEquity, last quarter 1.09b)
Debt / EBITDA = 1.73 (negative EBITDA) (Net Debt -271.7m / EBITDA -156.7m)
Debt / FCF = 2.58 (negative FCF - burning cash) (Net Debt -271.7m / FCF TTM -105.4m)
Total Stockholder Equity = 1.03b (last 4 quarters mean from totalStockholderEquity)
RoA = -13.26% (Net Income -160.7m / Total Assets 1.19b)
RoE = -15.55% (Net Income TTM -160.7m / Total Stockholder Equity 1.03b)
RoCE = -15.15% (EBIT -160.7m / Capital Employed (Equity 1.03b + L.T.Debt 27.2m))
RoIC = -12.28% (negative operating profit) (NOPAT -127.0m / Invested Capital 1.03b)
WACC = 9.48% (E(3.19b)/V(3.22b) * Re(9.56%) + (debt cost/tax rate unavailable))
Discount Rate = 9.56% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 17.25%
Fair Price DCF = unknown (Cash Flow -105.4m)
EPS Correlation: 12.78 | EPS CAGR: 7.34% | SUE: 1.19 | # QB: 2
Revenue Correlation: -21.54 | Revenue CAGR: 210.6% | SUE: 4.0 | # QB: 1
EPS next Quarter (2026-03-31): EPS=-0.94 | Chg30d=-0.008 | Revisions Net=-1 | Analysts=7
EPS next Year (2026-12-31): EPS=-3.56 | Chg30d=-0.046 | Revisions Net=-1 | Growth EPS=-183.6% | Growth Revenue=-76.0%

Additional Sources for IDYA Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle